Investors looking for long-term gains may find value in currently struggling stocks, as buying at lower prices can yield significant returns as companies recover. This strategy emphasizes patience, allowing investors to capitalize on quality firms during downturns without the pressure of short-term market fluctuations.
Pfizer (PFE) and UnitedHealth Group (UNH) are two healthcare stocks that exemplify this approach. Pfizer, trading at just 9x forward earnings, is poised for recovery following a revenue decline due to reduced demand for its COVID-19 products. The company’s strategic acquisitions, including Seagen and Metsera, position it for growth in oncology and obesity treatments. Meanwhile, UnitedHealth, trading at 15x forward earnings, is implementing measures to address recent operational challenges, leveraging its dual business model to enhance revenue prospects.
For long-term investors, both Pfizer and UnitedHealth present attractive entry points, potentially leading to substantial gains as they navigate their respective recoveries.
Source: fool.com